ATM, ATM serine/threonine kinase, 472

N. diseases: 684; N. variants: 974
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 AlteredExpression group BEFREE In Capan-1 mouse xenograft model, AZD1775 plus AZD0156 (ATM inhibitor) treatment reduced tumor growth and downregulated tumor expression of PD-L1, CMTM6, CD163, and CXCR2, all of which contribute to tumor immune evasion. 31291716 2020
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation group BEFREE We found enrichment of ATM mutations in ICPI-refractory tumors (P=0.01) to correlate with worse survival (4.2 vs. 10 mo, P=0.03). 31567705 2020
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE Therapeutic Potential of the microRNA-ATM Axis in the Management of Tumor Radioresistance. 31767626 2020
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation group BEFREE However, absence of the familial microdeletion in at least one affected family member suggests that ATM deletions are unlikely the sole contributing factor influencing tumor development in affected individuals. 31671381 2020
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE A proximity ligation assay further confirmed an association between ATM and EZH2 in tumors of patients with an increased disease-free survival. 31704732 2020
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE ATM is a well-established tumour suppressor. 31565865 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation group BEFREE Regarding qualitative imaging features, on univariate analysis, tumor location was significantly associated with APC (p = 0.032) and RASA1 mutation (p = 0.032); CRM status was significantly associated with ATM mutation (p = 0.021); and lymph node metastasis was significantly associated with BRCA2 (p = 0.046) mutation. 30927944 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE These results provide new insight into PDA initiation and reveal ATDC as a potential target for preventing early tumor-initiating events. 31048544 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation group BEFREE The prognostic impact of ATM mutations was independent from TP53 mutational status and primary tumor location. 30814645 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE Tumor immunogenicity was evaluated after ATM inhibition alone and in combination with radiation by assessing TBK1 and Type I interferon (T1IFN) signaling as well as tumor growth following PD-L1/PD-1 checkpoint inhibition. 31101760 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation group BEFREE In addition, we analyzed seven prostate cancer biopsies that were either BRCA2 or ATM-mutated in comparison with wild-type tumors. 31549213 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE A phase II study (Study 39; NCT01063517) designed to investigate the combination olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer did not meet its primary endpoint of progression-free survival; however, an improvement in the secondary endpoint of overall survival was recorded with a greater overall survival benefit noted in patients with ATM-negative tumors. 31206368 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE Although the angiotensin II (AngII)/AT1 receptor system is best known for mediating blood pressure and body water/electrolyte balance it also facilitates tumor vascularization and growth by stimulating the expression of VEGF. 30914029 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 AlteredExpression group BEFREE In MYC over expressed tumours, high ATR or low ATM levels were associated with aggressive breast cancer features such as higher tumour grade, de-differentiation, pleomorphism, high mitotic index, high-risk Nottingham Prognostic Index, triple negative and basal-like breast cancers (all adjusted p values < 0.05). 30746633 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE Oncogene-induced replication stress serves as a tumour specific vulnerability and rationale for the clinical development of inhibitors targeting the DNA damage response (DDR) kinases (CHK1, ATR, ATM and WEE1). 31500184 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE Cells and tissues lacking ATM are prone to tumor development and enhanced tumor cell migration and invasion. 30553448 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 AlteredExpression group BEFREE Abnormal DNA damage response protein expression, defined as loss of any one of NBS1, BRCA1, ATM, and/or abnormal p53 expression, was observed in 258 of 399 evaluable cases (64.7%) and was significantly associated with higher tumor grade, larger tumor size, and ER-negative, and/or PR-negative status. 30671767 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 AlteredExpression group BEFREE ATM is a kinase activated by autophosphorylation upon DNA doublestrand breaks arising from errors during replication, byproducts of metabolism, chemotherapy or ionizing radiations; TP53 is one of the most popular tumor suppressor, with a preeminent role in DNA damage response and repair. 29369420 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE Genomic alterations significantly co-occurred in the tumor suppressor gene ATM with the following genes: SMARCB1, EGFR exon 7, RET and KDR. 30093964 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE Network interactions of proteins involved in tumor growth (Ki67, ATM) and/or affect the oxidation state of the cell (HIF-1a, iNOS, aGluc) were revealed, that may contribute to the risk of developing acute radiation dermatitis. 29491093 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE In addition, we identified a small subset of LS polyps with high mutational and neoantigen rates that were comparable to hypermutant tumors and displayed additional checkpoint (CTLA4 [cytotoxic T-lymphocyte-associated protein 4]) and neoantigens involved in DNA damage response (ATM and BRCA1 signaling). 29710228 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation group BEFREE To evaluate the role of constitutive epigenetic changes in normal body cells of BRCA1/BRCA2-mutation negative patients, we have developed a deep bisulfite sequencing assay targeting the promoter regions of 8 tumor suppressor (TS) genes (BRCA1, BRCA2, RAD51C, ATM, PTEN, TP53, MLH1, RB1) and the estrogene receptor gene (ESR1), which plays a role in tumor progression. 29659014 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage. 29769307 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 GeneticVariation group BEFREE Furthermore, variants of ATM gene had smaller tumor size, lower pathologic T stage at presentation, and more favorable surrogate molecular subtype compared to variants of other genes. 28986972 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.500 Biomarker group BEFREE Conditioned medium mimicking the tumor microenvironment augments chemotherapeutic resistance via ataxia‑telangiectasia mutated and nuclear factor‑κB pathways in gastric cancer cells. 30106453 2018